Aaron Berger, MD
Urology · Chicago Ridge, ILNPI 1720122005
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $370,811 of the $582,718 with a category attached, or 63.6%. 60 manufacturers reported payments, led by Johnson & Johnson at 37.0% of the total. 2025 is the largest year on record at $176,899, 2.8 times the $62,288 reported in 2019. Among urology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,779 payments — averaging $327.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$216K
- Bayer$81K
- Astellas Pharma US Inc$81K
- Ferring Pharmaceuticals Inc.$42K
- Pfizer$41K
- Accord Healthcare, Inc.$33K
- plus $89K from 54 others
Across 104 payments — averaging $14,802 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.3M
- Sumitomo Pharma America, Inc.$177K
- Dendreon Pharmaceuticals LLC$86K
- Pfizer$9K
What the payments were for
- Consulting fees$123,71821%
- Speaking & faculty fees$370,81164%
- Travel & lodging$44,8428%
- Food & beverage$42,5827%
- Education$7650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$582,718 in reported general payments places this provider in the 95th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 617 | $8,789,858 |
| XtandiEnzalutamide | 481 | $6,442,234 |
| NubeqaDarolutamide | 199 | $2,525,074 |
| OrgovyxRelugolix | 495 | $1,276,415 |
| Abiraterone Acetate | 200 | $469,849 |
| ZytigaAbiraterone Acetate | 15 | $157,427 |
| MyrbetriqMirabegron | 132 | $78,781 |
| GemtesaVibegron | 58 | $43,582 |
| Tamsulosin Hcl | 941 | $12,366 |
| Solifenacin Succinate | 246 | $11,520 |
| XyostedTestosterone Enanthate | 13 | $7,768 |
| Oxybutynin Chloride ErOxybutynin Chloride | 352 | $7,104 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 29 | $6,856 |
| Darifenacin ErDarifenacin Hydrobromide | 25 | $4,550 |
| Dutasteride | 129 | $3,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Zytiga | $215,798 | $8,947,285632 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $80,550 | $6,521,014613 claims |
| BayerNubeqa | $80,940 | $2,525,074199 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $20,526 | $1,319,996553 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,339 | $469,849200 claims |
| Antares Pharma, Inc.Xyosted | $920 | $7,76813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 550 urology providers in Illinois.
Other urology in Chicago Ridge
- Ikechukwu OguejioforChicago Ridge$26K
- Mark BrandtPark Ridge$1.3M
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Kevin McVarySpringfield$372K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.